Bristol Myers Squibb reported Q3 2024 revenues of $11.9 billion, increasing 8% YoY (10% excluding foreign exchange), driven by Growth Portfolio revenues of $5.8 billion (+18% YoY) and strong Eliquis performance. GAAP EPS was $0.60 and Non-GAAP EPS was $1.80, including a net impact of -$0.09 from Acquired IPRD charges and licensing income.The Growth Portfolio showed robust momentum with significant gains across key products: Reblozyl (+80%), Breyanzi (+143%), Camzyos (+129%), and Opdualag (+40%). The Legacy Portfolio remained stable with Eliquis revenues up 11% to $3.0 billion, while Sprycel declined 44% due to generic erosion.The company raised its 2024 revenue guidance to approximately +5% (+6% excluding foreign exchange) and increased its Non-GAAP EPS range to $0.75-$0.95. Notable achievements include U.S. approval of Cobenfy for schizophrenia treatment, marking the first new pharmacological approach in decades.

Bristol Myers Squibb reported Q3 2024 revenues of $11.9 billion, increasing 8% YoY (10% excluding foreign exchange), driven by Growth Portfolio revenues of $5.8 billion (+18% YoY) and strong Eliquis performance. GAAP EPS was $0.60 and Non-GAAP EPS was $1.80, including a net impact of -$0.09 from Acquired IPRD charges and licensing income.The Growth Portfolio showed robust momentum with significant gains across key products: Reblozyl (+80%), Breyanzi (+143%), Camzyos (+129%), and Opdualag (+40%). The Legacy Portfolio remained stable with Eliquis revenues up 11% to $3.0 billion, while Sprycel declined 44% due to generic erosion.The company raised its 2024 revenue guidance to approximately +5% (+6% excluding foreign exchange) and increased its Non-GAAP EPS range to $0.75-$0.95. Notable achievements include U.S. approval of Cobenfy for schizophrenia treatment, marking the first new pharmacological approach in decades.